SCHEMBL4259059

SCHEMBL4259059

CC(CNCCCn1nc2c(c1C(=O)OC(=O)C(F)(F)F)CCc1cnccc1-2)c1ccc(Cl)cc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4265871 0.93 TAAR1 (0.35)
Trifluoroacetic Acid SCHEMBL4259057 0.89 CACNA1G (0.31)
SCHEMBL1656586 0.88 ROCK2 (0.34)
SCHEMBL15453745 0.87 CACNA1G (0.33)
SCHEMBL4264416 0.87 ROCK2 (0.36)
SCHEMBL1658751 0.87 ROCK2 (0.34)
SCHEMBL4257728 0.87 HPGD (0.30)
SCHEMBL4264032 0.86 ALDH1A1 (0.30)
SCHEMBL6792403 0.85 ROCK2 (0.35)
SCHEMBL6793563 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 US claimed
US-8440610-B2 Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2013-05-14 US disclosed
US-20120252737-A1 Methods for Diagnosing and Treating Cancer MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-10-04 US disclosed
US-20090010927-A1 Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-01-08 US disclosed
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 US disclosed